CN100344288C - Compound pain-stopping and inflammation-diminishing anticarcinogen capsule - Google Patents
Compound pain-stopping and inflammation-diminishing anticarcinogen capsule Download PDFInfo
- Publication number
- CN100344288C CN100344288C CNB02155496XA CN02155496A CN100344288C CN 100344288 C CN100344288 C CN 100344288C CN B02155496X A CNB02155496X A CN B02155496XA CN 02155496 A CN02155496 A CN 02155496A CN 100344288 C CN100344288 C CN 100344288C
- Authority
- CN
- China
- Prior art keywords
- western medicine
- cancer
- present
- pain
- grade
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to type III anodyne anti-inflammation and anticancer western medicine which can be used for alleviating cancer pain during the period of Stage II to Stage III and improving the survival quality of patients with cancer, and the western medicine can improve the symptom of digestive tract cancer, prolong the survival time, and replace morphine but have no dependent performance. The western medicine is oral administration medicine without toxin, anesthesia, essence or discharge. The western medicine can alleviate pain of Reynaud's disease, vasospasm (comprising cerebral vessel spasm) and herpes zoster, and can have obvious therapeutic effect on diabetes lower than the fourth grade (zero to fifth grade in a six-grading method), rheumatism, rheumatoid disease, shoulder periarthritis and phlebitis.
Description
Technical field
The present invention relates to a kind of powerful pain-stopping, antiinflammatory, anticancer so that can be used for the oral medicine of cancer " II～III step analgesia ".
Background technology
The medical scientific research worker is seeking to be used for the Drug therapy of cancer " II～III step analgesia " always over more than 100 year, always round morphine or change the analgesic of morphine structure, spiritual class medicines structure, so that the evil drugs of ice and so on harm humans appear.The medicine that also has through changing morphine, opium structure add nonsteroid anti-inflammatory drugs (NSAID) as: add " paracetamol ﹠ codeine " of " acetaminophen " and prescription that the U.S. " Johnson ﹠ Johnson " develops recently all has the ADR of the seemingly untoward reaction (ADR) " paracetamol ﹠ codeine " of morphine little for " Taylor is peaceful " these medicines that " oxycodone " adds " acetaminophen " by " codeine ", but analgesic activity less than " Taylor is peaceful " but in " Taylor is peaceful " " opium " the class ADR of " oxycodone " allow of no optimist.
Summary of the invention
It is reasonable to the purpose of this invention is to provide a kind of prescription, and theoretical foundation is reliable, and clinical proof curative effect is (P＜0.01) very obviously, prescription is simple, cost is low, draws materials and can end severe pain, altauna easily, can be used for cancer " II～III step analgesia " and the little oral medicine of ADR.
Prescription of the present invention is the acid of acetyl poplar, meticorten, acetaminophen.Finished product belong to each component raw material in proportion uniform mixing incapsulate.
24 hours LD of zoopery white mice of the present invention fasting
50=1.550g/kg.Clinical have very positive effect (P＜0.01) to the treatment of cancer " II～III step analgesia " at random, meets at random, contrasts, repeats.Analgesic effect to osteocarcinoma is better than morphine 30mg/d.so; Analgesic effect morphine to cancer of pancreas can't be compared especially, and this is that the present invention does not have this ADR because morphine is bad to the Oddi sphincter function, and the present invention has therapeutical effect to be to improve to gastric cancer or suppresses vomiting, analgesia and prolong survival period.
Theoretical foundation of the present invention is: pain patients cox, PG synzyme are higher than ordinary person, especially cancer patient, the aspirin molecular weight is little among the present invention, concentration height in cerebrospinal fluid, be easy to see through blood brain barrier, can act on pain sensation maincenter, but can only effect be arranged to mild pain, connect 1 grade of analgesic effect by 0～3 grade of VRS method and still can not reach the CR level, the prednisone that the present invention adds the first messenger strengthens second message,second messenger's amplification of cAMP, has given play to aspirin in the prescription and has strengthened the amplification analgesic effect that is geometrical progression in using than folk prescription.Extremely strong inhibition cox, PG synzyme, nervus centralis is played extremely strong analgesic activity; The analgesic effect of same acetaminophen is also acted on the second trustworthy historical record cAMP by first messenger's prednisone and is the geometrical progression amplification, play synergism with aspirin, rather than as the synergism that is algebraic series of nervus centralis pain relieving and the addition of peripheral nervous analgesic of morphine class and NSAID.
My selected aspirin and acetaminophen and do not select for use the aminophenazone class to be because the aminophenazone class have fearful granulocyte suppress can the pure man in the consequence at fatal position; It is to play same analgesic activity with them can reduce component dosage in the compound recipe that compound preparation of the present invention is selected aspirin and acetaminophen for use, folk prescription without excess dosage, in case single time spent of each component produce to the ADR of internal organs as: aspirin is to the ADR of stomach, kidney, and acetaminophen is to the ADR of liver; Select for use prednisone to be because the rapid-action t of prednisone
1/2Short, meaningfully work the anaphylaxis of amplifying NSAID effect and anti-NSAID with prednisone in a small amount, rather than with a large amount of GCS (as 10～20mg DXM) antiinflammatory action, single is not reach so strong analgesic effect far away with GCS, " Bao Shitai " of acetaminophen 325mg and ibuprofen 400mg compatibility was once fashionable for a time, but the child's incident that causes death of " FDA " report " acetaminophen " and " ibuprofen " that it is not promising that is seen generation repeatly.
Aspirin has anti-platelet aggregation that the platelet increasing of prednisone is had mutual cushioning effect in my prescription, aspirin has blood sugar reducing function slightly on to the influence of blood glucose, prednisone has the blood glucose of increasing slightly, so the ADR of this two medicines compatibility among them can be eased.The present invention with single there is no with the aspirin ratio prolong, clotting time, as protopathy or have bleeding tendency body constitution person to obey vitamin K simultaneously to get final product in clothes the present invention.Clothes the present invention can obey cimetidine 400～600mg if any gastric acid or stomach discomfort sense, to " aspirin " allergy being arranged or wrongly taking excessive person and can promptly obey " sodium bicarbonate " 4～8 grams, can alleviate within half an hour, can not obey the present invention to " aspirin " allergy sufferers.
Taboo compatibility of the present invention is: aminophenazone or contain aminophenazone component preparation.
The present invention is forbidden in hemorrhage, gastric ulcer, hypercortisolism.
The present invention is to the analgesic activity of cancer pain: pain can reach CR level (fully not bitterly) by VRS method classification (0～3 grade) analgesic activity to 0～1 grade, can reach PR～CR level to 1～3 grade of analgesic effect, as reaching 7～9 grades, far be better than " Taylor is peaceful " or " Morphine " of present listing by 0～10 grade of point-score analgesic effect of the present invention.
White mice of the present invention is 24h LD on an empty stomach
50=1.550g/kg.
Medicated powder 0.299 gram in the every capsules of the present invention, when painful 1～3,4 of maximum dose (adult's dosage).
The specific embodiment
Processing technology of the present invention is simple, presses GMP authentication workshop, raw material, flow process, quality monitoring.
Every capsules aspirin 0.195 gram of raw material preparation, acetaminophen 0.1 gram, prednisone 0.004 gram.
Claims (1)
1. a compound recipe powerful pain-stopping antiinflammatory anti-cancer capsule is characterized in that, is made up of following component in every compound recipe powerful pain-stopping antiinflammatory anti-cancer capsule: aspirin medicated powder 0.195 gram, acetaminophen medicated powder 0.1 gram, prednisone medicated powder 0.004 gram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02155496XA CN100344288C (en) | 2002-12-16 | 2002-12-16 | Compound pain-stopping and inflammation-diminishing anticarcinogen capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB02155496XA CN100344288C (en) | 2002-12-16 | 2002-12-16 | Compound pain-stopping and inflammation-diminishing anticarcinogen capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1421233A CN1421233A (en) | 2003-06-04 |
| CN100344288C true CN100344288C (en) | 2007-10-24 |
Family
ID=4752661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02155496XA Expired - Fee Related CN100344288C (en) | 2002-12-16 | 2002-12-16 | Compound pain-stopping and inflammation-diminishing anticarcinogen capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100344288C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100444854C (en) * | 2006-05-31 | 2008-12-24 | 冯喜平 | Ointment for treating phlebitis and method for preparing same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110914A (en) * | 1994-04-27 | 1995-11-01 | 李广义 | Compound capsule for fever release pain stop and anti-inflammation |
-
2002
- 2002-12-16 CN CNB02155496XA patent/CN100344288C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110914A (en) * | 1994-04-27 | 1995-11-01 | 李广义 | Compound capsule for fever release pain stop and anti-inflammation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1421233A (en) | 2003-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rumack | Anticholinergic poisoning: treatment with physostigmine | |
| CN100553665C (en) | A kind of Chinese medicine medicine for the treatment of pharyngolaryngitis | |
| CN102008482A (en) | Compound preparation containing valsartan for treating hypertension | |
| CN100344288C (en) | Compound pain-stopping and inflammation-diminishing anticarcinogen capsule | |
| CN102008709A (en) | Moexipril-contained compound preparation for treating hypertension | |
| CN101297900A (en) | Medicine new purpose of Ampelopsis Sinica stem leaf total flavones and single component myricetin | |
| CN1255151C (en) | Compound Longxue scorpion and preparation method thereof | |
| US20110064813A1 (en) | Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet | |
| CN101972259B (en) | Brucine and application of derivatives thereof in preparation of drugs for treating alcoholic abuse and dependence | |
| Adams et al. | Ambulatory use of high-dose intravenous morphine for severe pain | |
| CN101322706B (en) | Applications of hexa-gelsemicine in preparing medicament for treating chronic ache | |
| CN1221276C (en) | Compound Huangyangning (Chinese littleleaf box) small pills | |
| CN1686198A (en) | Oral administration medicinal preparation prepared using notoginseng, salvia root and erigeron breviscapus extracts | |
| CN103800341A (en) | Combined medicine for preventing and treating tumors | |
| CN1054746C (en) | Method for application of copper salicylacetate | |
| CN1234360C (en) | Complementary gain pain-killing medicine | |
| CN1443536A (en) | Aspirin compound preparation for resisting inflammation, stopping pain and resisting thrombus | |
| JPS63196517A (en) | Antihypoxic and application | |
| RU2611383C2 (en) | Combined preparation for elimination of symptoms and treating acute respiratory viral infections and influenza | |
| Aphale et al. | Conventional Homeopathic Medicine and Its Relevance to Modern Medicine. | |
| CN104888068A (en) | Medicine for treatment or adjuvant treatment of acquired immune deficiency syndrome and preparation method and application method of medicine | |
| CN1823760A (en) | Use of artemisia apiacea kind medicine for treating gliosis | |
| CN1094620A (en) | The Chinese patent medicine Liu Hua ai huixiangdan of the treatment esophageal carcinoma | |
| CN105832771B (en) | A kind of drug and preparation method thereof for treating gastrointestinal candidiasis | |
| CN1425412A (en) | Compound oral thrombolytic preparation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Guangyi Document name: Notification of Termination of Patent Right |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071024 Termination date: 20101216 |